Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Semin Hematol. 2014 May 15;51(3):177–187. doi: 10.1053/j.seminhematol.2014.05.004

Table 1.

Evidence for co-segregation and mutual exclusivity of genetic alterations in CLL

Alterations associated with M-IGHV8,9,15,22
Pathway Alteration Co-Segregation Mutual Exclusivity Location
Chromatin modification CHD2 15q26
Inflammatory pathways MYD88 Del13q9,22,25 SF3B1,25 NOTCH125 3p22
Alterations associated with U-IGHV8,9,11,14,15,22,25,27,28,82,83
Pathway Alteration Co-Segregation Mutual Exclusivity Location
DNA damage response, cell cycle control ATM Del(11q)9 11q22-q23*
BIRC3 Del(11q)2,25 TP53, 2,24,30 NOTCH1,24 SF3B124 11q22*
POT1 SF3B114 7q31.33
TP53 Del(1 7p) 2,9,25,49,80–82 SF3B1,28 Tris(12),49 BIRC324 17p13.1*
mRNA processing SF3B1 Del(11q)9,22 MYD8825, Tris(12)28 NOTCH1 22,25,27,79, TP5330 2q33.1
XPO1 NOTCH18 2p15
NOTCH signaling NOTCH1 Tris(12),2,9,22,26,27,29 XPO1,8 TP5311,26 SF3B1,22,25,27,79 MYD88,25 TP53,29 BIRC3,24 Del(13q)26 9q34.3
FBXW7 Tris(12)9,22 SF3B1,22 NOTCH19 4q31.3
*

involved in corresponding common chromosomal alterations